Rein Therapeutics
Austin
About Rein Therapeutics
Rein Therapeutics is a biopharmaceutical company that is developing therapies for pulmonary and fibrotic diseases. Its pipeline includes LTI-03 for idiopathic pulmonary fibrosis, LTI-01 for pleural effusion, and early programs for cystic fibrosis and systemic fibrosis using peptide and proenzyme approaches.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $21.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2025)
- Ticker: nasdaq:RNTX
- Website: reintx.com
- Phone: 1 (737) 802-1989
Industries & Categories
Biopharma, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/rein-therapeutics-58662 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.